- VT-111 results demonstrate statistically significant reduction in two key biomarkers of cardiac damage - LONDON, ON, Dec. 16 /PRNewswire/ - Viron Therapeutics Inc.

LONDON, ON, March 16 /PRNewswire/ - Viron Therapeutics Inc. announced that VT-346, an anti-TNF protein therapeutic, demonstrated positive results in a pivotal proof of concept study in the gold standard transgenic mouse model for arthritis.

LONDON, ON, Dec. 22 /PRNewswire/ - Viron Therapeutics Inc., a biotechnology company pioneering the development of virally-derived protein therapeutics, today announced that it has been granted U.S. patents related to three of its drug candidates, VT-111, VT-346 and VT-384.

VT-111 significantly reduces key cardiac enzymes at multiple time points after stent placement; Data presented at American Heart Association 2009 Scientific Sessions LONDON, ON, Nov.

LONDON, ON, Nov. 11 /PRNewswire/ - Viron Therapeutics Inc., a biopharmaceutical company pioneering the development of viral protein therapeutics, announced today that the Company's research collaborator, Dr.